Publications in collaboration with researchers from Essen University Hospital (1)

2018

  1. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 4, pp. 510-520